Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Diuretics: adverse respiratory-related morbidity and mortality

Diuretics: adverse respiratory-related morbidity and mortality Reactions 1680, p6 - 2 Dec 2017 Diuretics: adverse respiratory- related morbidity and mortality In elderly patients with COPD, treatment with oral diuretics is associated with increased rates of respiratory-related morbidity and mortality, according to study results reported in the British Journal of Clinical Pharmacology, particularly treatment with loop diuretics. The retrospective cohort study used health administrative data from Ontario, Canada, between 1 April 2008 and 30 April 2013 to identify 99 766 patients ≥66 years of age. Following propensity score adjustment using 55 covariates, the 51 431 new users of diuretics were matched with 48 473 nonusers. Loop diuretics were the most commonly prescribed drug subclass (58.6%), followed by thiazides (38.4%), potassium-sparing diuretics (5.8%) and anhydrase inhibitors (2.0%). Within 30 days of starting treatment, hospitalisation for COPD/pneumonia occurred in 1.9% of diuretic users and 1.5% of nonusers (hazard ratio [HR] 1.22; 95% CI 1.07, 1.40; p=0.003). Diuretic users also had a higher risk of ER visits for COPD/pneumonia (HR 1.35; 1.18, 1.56; p<0.001), COPD/pneumonia mortality (HR 1.41; 1.04, 1.92; p=0.03) and all-cause mortality (HR 1.20; 1.06, 1.35; p=0.003), but no significantly increased risk of ICU admission for COPD/pneumonia, or outpatient respiratory exacerbation. Sensitivity analyses revealed that results were http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Diuretics: adverse respiratory-related morbidity and mortality

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017

Diuretics: adverse respiratory-related morbidity and mortality

Abstract

Reactions 1680, p6 - 2 Dec 2017 Diuretics: adverse respiratory- related morbidity and mortality In elderly patients with COPD, treatment with oral diuretics is associated with increased rates of respiratory-related morbidity and mortality, according to study results reported in the British Journal of Clinical Pharmacology, particularly treatment with loop diuretics. The retrospective cohort study used health administrative data from Ontario, Canada, between 1 April 2008 and 30 April 2013 to...
Loading next page...
1
 
/lp/springer_journal/diuretics-adverse-respiratory-related-morbidity-and-mortality-s606gZV60B

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-017-38937-6
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p6 - 2 Dec 2017 Diuretics: adverse respiratory- related morbidity and mortality In elderly patients with COPD, treatment with oral diuretics is associated with increased rates of respiratory-related morbidity and mortality, according to study results reported in the British Journal of Clinical Pharmacology, particularly treatment with loop diuretics. The retrospective cohort study used health administrative data from Ontario, Canada, between 1 April 2008 and 30 April 2013 to identify 99 766 patients ≥66 years of age. Following propensity score adjustment using 55 covariates, the 51 431 new users of diuretics were matched with 48 473 nonusers. Loop diuretics were the most commonly prescribed drug subclass (58.6%), followed by thiazides (38.4%), potassium-sparing diuretics (5.8%) and anhydrase inhibitors (2.0%). Within 30 days of starting treatment, hospitalisation for COPD/pneumonia occurred in 1.9% of diuretic users and 1.5% of nonusers (hazard ratio [HR] 1.22; 95% CI 1.07, 1.40; p=0.003). Diuretic users also had a higher risk of ER visits for COPD/pneumonia (HR 1.35; 1.18, 1.56; p<0.001), COPD/pneumonia mortality (HR 1.41; 1.04, 1.92; p=0.03) and all-cause mortality (HR 1.20; 1.06, 1.35; p=0.003), but no significantly increased risk of ICU admission for COPD/pneumonia, or outpatient respiratory exacerbation. Sensitivity analyses revealed that results were

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.